NASDAQ · IMTX
Immatics N.V.
$7.24-$0.07 (-0.96%)
Immatics N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.66% below the high.
Loading market information…
NASDAQ · SEEL · USD
Stock price, earnings
Quote as of Nov 18, 2024, 08:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Seelos Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Seelos Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the discovery, development, and eventual commercialization of innovative therapies. These treatments primarily target central nervous system (CNS), respiratory, and various other medical conditions. The company's pipeline includes several key clinical-stage candidates. Foremost among these is SLS-002, an intranasally administered racemic ketamine, being investigated for rapidly alleviating acute suicidal ideation and behavior in individuals with major depressive disorder (MDD). Another significant program, SLS-005, acts as a protein stabilizer, addressing amyotrophic lateral sclerosis (ALS) and Sanfilippo syndrome. Additionally, SLS-006 is a partial dopamine agonist under development for the treatment of Parkinson's disease (PD). Beyond its clinical efforts, Seelos maintains a robust preclinical portfolio exploring novel mechanisms. This includes SLS-007, an anti-alpha-synuclein peptidic inhibitor designed to combat Parkinson's disease, and SLS-008, an orally bioavailable antagonist targeting chemoattractant receptor-homologous molecule, intended for chronic inflammatory conditions such as asthma and specific pediatric orphan diseases. Other early-stage candidates comprise SLS-004 for Parkinson's disease; SLS-010, an oral histamine H3A receptor antagonist aimed at narcolepsy and related sleep disorders; and SLS-012, an injectable formulation for managing post-operative pain. Founded in 1987, Seelos Therapeutics, Inc. operates from its headquarters situated in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:42 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2022 | Mar 10, 2023 | -$0.17-30.77% vs estimate | $0.00 |
|---|
| Q3 2022 | Nov 10, 2022 | -$6.13-6,030.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.24-$0.07 (-0.96%)
Immatics N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.66% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.47$0.00 (0.0%)
ProSomnus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.0% below the high.
$0.07-$0.10 (-60.05%)
TFF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.41% below the high.
$0.50$0.00 (0.0%)
TC Biopharm (Holdings) Plc’s quoted price sits in the lower half of its reported 52-week range, 99.9% below the high.
$0.16+$0.02 (+12.4%)
Virios Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
$0.31+$0.08 (+36.94%)
Akerna Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.46% below the high.
$0.01-$0.01 (-36.84%)
Bellerophon Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.0% below the high.
